Omeros Corporation (OMER) Stock

Understand Omeros Corporation: how it makes money

Omeros develops protein therapeutics for rare complement-mediated diseases and transplant complications, selling its lead drug Yartemlia to transplant centers and advancing Narsoplimab in Phase III. Revenue is still pre-scale, built on Novo Nordisk partnership milestones and early adopter uptake, so the business lives or dies on market access in a very small patient pool.

The profit engine is a near-zero-volume direct-to-transplant-center model where gross margins run 97 percent but the patient population is so small that 340B discounts, J-code assignment, and NTAP coverage decisions (not manufacturing capacity) are the binding constraint on converting that margin into cash.

Business quality (Solid): A 97 percent gross margin, 14x P/E below the sector, and 107 percent ROE signal improving financial quality, but the 0.3 percent operating margin and absence of revenue guidance mean the company is still in the fragile early-commercial phase where a single payer decision can swing the P&L.

Valuation: At 14× earnings, OMER trades 18% below the Pharmaceutical Products average (17×).

Bull case

• Cash flow inflection within 18 months: Management stated on the Q1 FY26 call that Yartemlia was cash flow positive in Q1 and could make the entire company cash flow positive within 18 months, meaning the commercial engine is already generating enough margin to cover operating costs.
• Novo partnership de-risks near-term cash: Novo Nordisk provided a $240 million upfront payment and offers another $100 million in near-term milestones, giving Omeros a multi-year funding runway that is independent of Yartemlia sales velocity.
• Trading 18 percent below sector: At a P/E of 14.0x versus the Pharmaceutical Products industry average of 17.1x (18 percent below), the stock embeds skepticism about revenue durability while the 97 percent gross margin and positive cash flow trend argue the discount may be premature.

Bear case

• No revenue visibility yet: Management withheld revenue guidance on the Q1 FY26 call while market access and physician adoption develop, and the company remains loss-making excluding noncash derivative gains, so there is no concrete number to anchor a valuation thesis.
• 340B erodes effective margins: Management flagged that gross-to-net adjustments are expected to increase as 340B program participation grows, which will compress the realized price below the 97 percent headline gross margin and slow the path to sustained profitability.
• Earnings muddled by derivatives: Reported earnings remain exposed to volatile, noncash derivative remeasurements tied partly to the stock price, making it difficult to separate true operating performance from accounting noise in any single quarter.

Omeros Corporation earnings call transcripts

• OMER Q1 FY26 earnings call transcript (reported 2026-05-13) · analysis

All OMER earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Elicio Therapeutics, Inc. (ELTX)
• Atossa Therapeutics, Inc. (ATOS)
• GeoVax Labs, Inc. (GOVX)
• Cyclerion Therapeutics, Inc. (CYCN)
• Dianthus Therapeutics, Inc. (DNTH)
• Cocrystal Pharma, Inc. (COCP)
• Oramed Pharmaceuticals Inc. (ORMP)
• Sagimet Biosciences Inc. (SGMT)